Summary by Moomoo AI
CStone Pharmaceuticals adopted the sixth amended and restated articles of association on June 18, 2024, further improving the company's governance structure. The company currently has several Stock-based Incentive plans, including a pre-IPO incentive plan, an employee shareholding plan after the IPO, and a post-IPO restricted stock award plan.The company maintains a strategic partnership with Pfizer Hong Kong Limited and strictly adheres to the standards of the code of conduct for Directors’ securities trading as stipulated in Appendix C3 of the Hong Kong Listing Rules, while implementing the code of conduct for Director securities trading.In terms of equity structure, the company issues common stock with a par value of $0.0001 per share and manages treasury shares in accordance with listing rules. The company has established a clear governance framework and has explicitly defined relationships with related parties, controlling shareholders, contacts, subsidiaries, and major Shareholders.
